The molecular pathology of p53 in primitive neuroectodermal tumours of the central nervous system

被引:11
作者
Burns, ASYW [1 ]
Jaros, E
Cole, M
Perry, R
Pearson, AJ
Lunec, J
机构
[1] Univ Newcastle Upon Tyne, Sch Med, Canc Res Unit, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[2] Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England
[3] Univ Newcastle Upon Tyne, Dept Stat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[4] Royal Victoria Infirm, Dept Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England
关键词
central primitive neuroectodermal tumours; p53; protein; DNA sequencing; Waf-1; Bax; Bcl-2;
D O I
10.1038/sj/bjc/6600151
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One hundred and one pre-treatment primary central primitive neuroectodermal tumours were analysed for the expression of p53 protein by immunohistochemistry using the monoclonal antibody DO-7. The staining intensity was classified into four groups: strong, medium, weak and negative and strong staining intensity was associated with the poorest survival. DNA sequencing of the p53 gene was per-formed in 28 cases representing all four staining groups. Mutations were found in only three of the strong staining tumours suggesting that DNA mutations were not common events and that in the majority of the tumours with over-expressed p53, the protein was likely to be wild-type, Results of immunohistochemistry showed a significantly positive relationship between the expression of p53 and Bax and Bcl-2 proteins, but not Waf-1. Multivariate analyses supported the prognostic value of p53 immunostaining in central primitive neuroectodermal tumours and also of age and gender of patients. (C) 2002 Cancer Research UK.
引用
收藏
页码:1117 / 1123
页数:7
相关论文
共 33 条
[1]  
ADESINA AM, 1994, CANCER RES, V54, P5649
[2]   MICROSATELLITE ANALYSIS OF LOSS OF HETEROZYGOSITY ON CHROMOSOMES 9Q, 11P AND 17P IN MEDULLOBLASTOMAS [J].
ALBRECHT, S ;
VONDEIMLING, A ;
PIETSCH, T ;
GIANGASPERO, F ;
BRANDNER, S ;
KLEIHUES, P ;
WIESTLER, OD .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1994, 20 (01) :74-81
[3]   Stabilization of wild-type p53 by hypoxia-inducible factor 1α [J].
An, WG ;
Kanekal, M ;
Simon, MC ;
Maltepe, E ;
Blagosklonny, MV ;
Neckers, LM .
NATURE, 1998, 392 (6674) :405-408
[4]  
BADIALI M, 1993, DIAGN MOL PATHOL, V2, P23, DOI 10.1097/00019606-199303000-00004
[5]   p21(WAF1) immunohistochemical expression in breast carcinoma: Correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival [J].
Barbareschi, M ;
Caffo, O ;
Doglioni, C ;
Fina, P ;
Marchetti, A ;
Buttitta, F ;
Leek, R ;
Morelli, L ;
Leonardi, E ;
Bevilacqua, G ;
DallaPalma, P ;
Harris, AL .
BRITISH JOURNAL OF CANCER, 1996, 74 (02) :208-215
[6]   MEDULLOBLASTOMA IN PEDIATRIC AGE - A SINGLE-INSTITUTION REVIEW OF PROGNOSTIC FACTORS [J].
CERVONI, L ;
CANTORE, G .
CHILDS NERVOUS SYSTEM, 1995, 11 (02) :80-84
[7]   ANALYSIS OF THE P53 TUMOR-SUPPRESSOR GENE IN HEPATOCELLULAR CARCINOMAS FROM BRITAIN [J].
CHALLEN, C ;
LUNEC, J ;
WARREN, W ;
COLLIER, J ;
BASSENDINE, MF .
HEPATOLOGY, 1992, 16 (06) :1362-1366
[8]   AN OPERATIVE STAGING SYSTEM AND A MEGAVOLTAGE RADIOTHERAPEUTIC TECHNIC FOR CEREBELLAR MEDULLOBLASTOMAS [J].
CHANG, CH ;
HOUSEPIAN, EM ;
HERBERT, C .
RADIOLOGY, 1969, 93 (06) :1351-+
[9]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[10]  
Gilbertson RJ, 1998, CANCER RES, V58, P3932